GlaxoSmithKline wanted to prove Zejula could keep ovarian cancer at bay in all women after initial chemotherapy, not just those with BRCA mutations. And it did: The PARP inhibitor cut the risk of progression by 38% across the study, and
read moreAstraZeneca’s Tagrisso is already rolling in EGFR-mutated lung cancer, but new survival data could help spur additional reimbursement. Saturday at the European Society for Medical Oncology annual meeting, the British drugmaker touted results showing that using Tagrisso instead of older
read moreIt was a decent idea: Team Tecentriq, the Roche checkpoint inhibitor, with its Exelixis-partnered MEK inhibitor Cotellic to treat melanoma. Unfortunately, the idea didn’t work out as planned—at least not when it came to beating the foe it chose to
read moreRight now, Merck’s Keytruda is the only immuno-oncology treatment approved solo in previously untreated non-small cell lung cancer. But Roche’s Tecentriq is looking to make it two. Friday, the Swiss drugmaker presented data showing Tecentriq could extend patients’ lives by
read moreMylan’s long-running EpiPen scandal has cast a shadow over the company as regulators and politicians have piled on. In an effort to clear the air, Mylan will pay the SEC $30 million to settle claims it did not quickly disclose
read moreWith three JAK inhibitors on the market—including AbbVie’s much anticipated follow-up to Humira, Rinvoq—cost-effectiveness watchdog ICER is raising questions about whether the new drugs are worth the cost. More: New RA drugs offer 'marginal' benefits at prices that are too
read more© 1994 - 2026 B.M. Pharmaceuticals